- Home
- AI vs AKRO Comparison
AI vs AKRO Comparison
Compare AI & AKRO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AI
- AKRO
- Stock Information
- Founded
- AI 2009
- AKRO 2017
- Country
- AI United States
- AKRO United States
- Employees
- AI N/A
- AKRO N/A
- Industry
- AI Computer Software: Prepackaged Software
- AKRO Biotechnology: Pharmaceutical Preparations
- Sector
- AI Technology
- AKRO Health Care
- Exchange
- AI Nasdaq
- AKRO Nasdaq
- Market Cap
- AI 3.5B
- AKRO 3.9B
- IPO Year
- AI 2020
- AKRO 2019
- Fundamental
- Price
- AI $23.61
- AKRO $54.20
- Analyst Decision
- AI Hold
- AKRO Strong Buy
- Analyst Count
- AI 15
- AKRO 6
- Target Price
- AI $30.00
- AKRO $82.50
- AVG Volume (30 Days)
- AI 8.9M
- AKRO 1.8M
- Earning Date
- AI 05-28-2025
- AKRO 08-08-2025
- Dividend Yield
- AI N/A
- AKRO N/A
- EPS Growth
- AI N/A
- AKRO N/A
- EPS
- AI N/A
- AKRO N/A
- Revenue
- AI $389,056,000.00
- AKRO N/A
- Revenue This Year
- AI $22.71
- AKRO N/A
- Revenue Next Year
- AI $18.89
- AKRO N/A
- P/E Ratio
- AI N/A
- AKRO N/A
- Revenue Growth
- AI 25.27
- AKRO N/A
- 52 Week Low
- AI $17.03
- AKRO $21.02
- 52 Week High
- AI $45.08
- AKRO $58.40
- Technical
- Relative Strength Index (RSI)
- AI 46.68
- AKRO 62.96
- Support Level
- AI $23.29
- AKRO $53.61
- Resistance Level
- AI $24.75
- AKRO $56.49
- Average True Range (ATR)
- AI 1.06
- AKRO 2.40
- MACD
- AI -0.29
- AKRO -0.08
- Stochastic Oscillator
- AI 9.17
- AKRO 65.93
About AI C3.ai Inc.
C3.ai Inc is an enterprise artificial intelligence company. The company provides software-as-a-service applications that enable customers to rapidly develop, deploy, and operate large-scale Enterprise AI applications across any infrastructure. It provides solutions under three divisions namely, The C3 AI Platform, which is an end-to-end application development and runtime environment for designing, developing, and deploying AI applications: C3 AI Applications, which is a portfolio of pre-built, extensible, industry-specific, and application-specific Enterprise AI applications: and C3 Generative AI, which combines the utility of large language models. Geographically the company derives revenue from North America, Europe, the Middle East and Africa, Asia Pacific, and the Rest of the World.
About AKRO Akero Therapeutics Inc.
Akero Therapeutics Inc is a clinical-stage biotechnology company focused on developing and commercializing transformative treatments for serious metabolic diseases with high unmet medical needs. Its focus is nonalcoholic steatohepatitis (MASH), or NASH, a disease without any approved therapies. The company's product candidate efruxifermin is an FGF21 analog with properties that have the potential to address the core processes underlying NASH pathogenesis.